PanGIA Biotech to Present AI-Driven Urine-Based Prostate Cancer Detection Platform at ASCO 2025

• PanGIA Biotech will present collaborative research on AI-enabled prostate cancer prediction using urine-based liquid biopsy at ASCO 2025 in Chicago.
• The presentation highlights the company's AI-driven diagnostic platform that integrates biomolecular pattern analysis and machine learning for non-invasive cancer detection.
• The PanGIA® platform is designed to detect and monitor cancers as early as Stage 1 using urine-based biomolecular profiling powered by machine learning algorithms.

PanGIA Biotech will showcase its AI-driven urine-based diagnostic platform for prostate cancer detection at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), scheduled for May 30–June 3, 2025, in Chicago, Illinois. The company announced that an abstract co-authored by researchers from PanGIA Biotech, Entopsis Inc., and Genetics Institute of America has been accepted for presentation.

ASCO Presentation Details

The abstract, titled "Development and validation of an AI-enabled prediction of prostate cancer (PCa) using urine-based liquid biopsy" (Abstract #3080), will be presented during the poster session on Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology. The presentation is scheduled for June 2, 2025, from 1:30–4:30 p.m. CDT at McCormick Place in Chicago.

Technology Platform and Innovation

The presentation highlights collaborative research contributing to PanGIA's AI-driven, urine-based diagnostic platform. The work integrates biomolecular pattern analysis and machine learning to support the development of scalable, non-invasive solutions in cancer care.

"This presentation reflects our focus on developing non-invasive, scalable diagnostics rooted in the promise of liquid biopsy innovation," said Holly Magliochetti, CEO of PanGIA Biotech. "We remain committed to advancing technologies that may support earlier cancer detection and improve access to care globally."

Platform Capabilities

The PanGIA® platform represents a transformative solution for detecting, monitoring, and managing diseases, including cancers as early as Stage 1. Powered by machine learning, this urine-based platform profiles biomolecular patterns to deliver accurate diagnostic insights. The technology is grounded in peer-reviewed research and R&D success, supported by patents for global diagnostic development.

PanGIA Biotech develops AI-integrated liquid biopsy technology designed for global scalability, with a vision to revolutionize disease detection and improve healthcare worldwide through non-invasive diagnostic solutions.